Storia in 5 fonti

Roche stakes $700M on Nurix’s protein-degrading drug

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Roche stakes $700M on Nurix’s protein-degrading drug

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

originale

Timeline cronologica

lunedì 8 giugno 2026·biopharmadive.com
Roche stakes $700M on Nurix’s protein-degrading drug
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
lunedì 8 giugno 2026·swissinfo.ch
Roche joins Californian Nurix oncology programme
Roche pledges $700 million to join research on the drug bexobrutideg.

Roche stakes $700M on Nurix’s protein-degrading drug

Confronto fonti

Roche stakes $700M on Nurix’s protein-degrading drug

Timeline cronologica

Roche stakes $700M on Nurix’s protein-degrading drug

Roche joins Californian Nurix oncology programme

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying